with integrated capabilities spanning research, manufacturing, development, and commercialization.
With a strong focus on rare disease areas, we are committed to delivering innovative therapies
that address unmet medical needs around the world.
Our Philosophy
“We create treatments that go beyond rare disease to solve the world's most complex healthcare challenges”
This renewed philosophy is built on two ideas we care deeply about - continuing to explore areas of medicine where no treatments yet exist, and expanding the reach of our innovations so they can support more patients, wherever they are.
With a renewed sense of purpose, each of us at JCR is moving forward—thinking boldly, acting with intention, and striving to close the gap in unmet medical needs. This is how we grow—together.
JCR at a Glance
Established
1975
Number of
Employees
985
Number of
Domestic and
Overseas Locations
24
Male-to-
Female
Ratio
60:40
Net sales
40.3billion yen
Capital
9.1billion yen
(As of March 31, 2026)
Global Presence
Leiden,
NETHERLANDS
San Diego,
USA
São Paulo,
BRAZIL
Japan
- Research Centers
- 3
- Manufacturing Sites
- 5
- Business Offices
- 6
- Sales Offices
- 7
Key Focus Areas
- Orphan Drugs
- Regenerative Medical Products
- Biosimilars
- Childhood Short Stature
- Lysosomal Storage Disorders
- Renal Anemia
JCR History
-
1975
The Founding Years: Fighting to Sustain the Urokinase Purification Business
-
1985
Transitioning to Recombinant Products, Paving the Way for Genetic Engineering
-
2010
Developing Japan's First Biosimilar Produced Using Completely Serum-Free Cell Culture
-
2016
Creating Japan's First Allogeneic Regenerative Medical Product After 13 Years of R&D
-
2021
Approval of the World's First Therapy Utilizing Proprietary Blood-Brain Barrier Technology
Core Strengths
01
Advancing Care for Rare Diseases
02
Proprietary Biotechnologies and Expertise
03
Commitment to Manufacturing Excellence
Focused Where the Need Is Greatest
For many people living with rare diseases, effective treatment options remain limited or simply do not exist. JCR focuses its science where the need is greatest, working to develop new therapies for patients whose medical needs have yet to be met.
Science that Goes the Distance
JCR has built deep expertise in biopharmaceuticals and a broad range of technologies, from recombinant proteins and AAV gene therapy to regenerative medicine and nucleic acids. Across three research sites in Kobe, our capabilities extend from molecular design and process development to analytics, formulation, clinical development, manufacturing, and commercialization. Bringing these capabilities together allows us to advance new therapies from early research all the way to patients.
Built to Make What We Discover
JCR manufactures pharmaceuticals to global quality standards across five production sites in Kobe. Our integrated capabilities from R&D through commercial manufacturing, together with investment in the next generation of production systems and external manufacturing partners, support reliable supply to patients.
Our Challenges
Taking Our Science Further
Rare diseases do not stop at borders, and neither should the possibilities of science.
By connecting our research, development, manufacturing, and commercial capabilities with partners around the world,
JCR is working to turn scientific advances into new treatment options.
The path is rarely simple. Yet every challenge we overcome
brings us closer to creating new possibilities for patients who are still waiting.
That is why we will keep moving forward.